Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): Design and early dosimetric results of a randomized, multi-centre phase-III study

Ditte Sloth Moller; Tine Bjørn Nielsen; Carsten Brink; Lone Hoffmann; Christina Maria Lutz; Mikkel Drogemuller Lund; Olfred Hansen; Tine Schytte; Azza Ahmed Khalil; Marianne Marquard Knap; Christa Haugaard Nyhus; Wiviann Ottosson; Patrik Sibolt; Svetlana Borissova; Mirjana Josipovic; Gitte Persson; Ane Lindegaard Appelt

doi:10.1016/j.radonc.2017.06.022

Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): Design and early dosimetric results of a randomized, multi-centre phase-III study

Ditte Sloth Moller, Tine Bjørn Nielsen, Carsten Brink, Lone Hoffmann, Christina Maria Lutz, Mikkel Drogemuller Lund, Olfred Hansen, Tine Schytte, Azza Ahmed Khalil, Marianne Marquard Knap, Christa Haugaard Nyhus, Wiviann Ottosson, Patrik Sibolt, Svetlana Borissova, Mirjana Josipovic, Gitte Persson, Ane Lindegaard Appelt

Xray and Neutron Science

13 Citations (Scopus)

40 Downloads (Pure)

Original language	English
Journal	Radiotherapy & Oncology
Volume	124
Issue number	2
Pages (from-to)	311-317
ISSN	0167-8140
DOIs	https://doi.org/10.1016/j.radonc.2017.06.022
Publication status	Published - Aug 2017

Keywords

NSCLC
Dose-escalation
Randomized phase-III trial

Access to Document

10.1016/j.radonc.2017.06.022

Heterogeneous_FDG-guided_dose-escalation_for_locally_advanced_NSCLC_2017_acceptedAccepted author manuscript, 180 KBLicence: CC BY-NC-ND
1-s2.0-S0167814017304334-mainFinal published version, 882 KB

Cite this

Moller, D. S., Nielsen, T. B., Brink, C., Hoffmann, L., Lutz, C. M., Lund, M. D., Hansen, O., Schytte, T., Khalil, A. A., Knap, M. M., Nyhus, C. H., Ottosson, W., Sibolt, P., Borissova, S., Josipovic, M., Persson, G., & Appelt, A. L. (2017). Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): Design and early dosimetric results of a randomized, multi-centre phase-III study. Radiotherapy & Oncology, 124(2), 311-317. https://doi.org/10.1016/j.radonc.2017.06.022

Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial) : Design and early dosimetric results of a randomized, multi-centre phase-III study. / Moller, Ditte Sloth; Nielsen, Tine Bjørn; Brink, Carsten et al.

In: Radiotherapy & Oncology, Vol. 124, No. 2, 08.2017, p. 311-317.

Research output: Contribution to journal › Journal article › Research › peer-review

Moller, DS, Nielsen, TB, Brink, C, Hoffmann, L, Lutz, CM, Lund, MD, Hansen, O, Schytte, T, Khalil, AA, Knap, MM, Nyhus, CH, Ottosson, W, Sibolt, P, Borissova, S, Josipovic, M , Persson, G & Appelt, AL 2017, 'Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): Design and early dosimetric results of a randomized, multi-centre phase-III study', Radiotherapy & Oncology, vol. 124, no. 2, pp. 311-317. https://doi.org/10.1016/j.radonc.2017.06.022

@article{1044d9e6116c4a08a3188d62be69587c,

title = "Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): Design and early dosimetric results of a randomized, multi-centre phase-III study",

keywords = "NSCLC, Dose-escalation, Randomized phase-III trial",

author = "Moller, {Ditte Sloth} and Nielsen, {Tine Bj{\o}rn} and Carsten Brink and Lone Hoffmann and Lutz, {Christina Maria} and Lund, {Mikkel Drogemuller} and Olfred Hansen and Tine Schytte and Khalil, {Azza Ahmed} and Knap, {Marianne Marquard} and Nyhus, {Christa Haugaard} and Wiviann Ottosson and Patrik Sibolt and Svetlana Borissova and Mirjana Josipovic and Gitte Persson and Appelt, {Ane Lindegaard}",

year = "2017",

month = aug,

doi = "10.1016/j.radonc.2017.06.022",

language = "English",

volume = "124",

pages = "311--317",

journal = "Radiotherapy & Oncology",

issn = "0167-8140",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial)

T2 - Design and early dosimetric results of a randomized, multi-centre phase-III study

AU - Moller, Ditte Sloth

AU - Nielsen, Tine Bjørn

AU - Brink, Carsten

AU - Hoffmann, Lone

AU - Lutz, Christina Maria

AU - Lund, Mikkel Drogemuller

AU - Hansen, Olfred

AU - Schytte, Tine

AU - Khalil, Azza Ahmed

AU - Knap, Marianne Marquard

AU - Nyhus, Christa Haugaard

AU - Ottosson, Wiviann

AU - Sibolt, Patrik

AU - Borissova, Svetlana

AU - Josipovic, Mirjana

AU - Persson, Gitte

AU - Appelt, Ane Lindegaard

PY - 2017/8

Y1 - 2017/8

KW - NSCLC

KW - Dose-escalation

KW - Randomized phase-III trial

U2 - 10.1016/j.radonc.2017.06.022

DO - 10.1016/j.radonc.2017.06.022

M3 - Journal article

C2 - 28688525

SN - 0167-8140

VL - 124

SP - 311

EP - 317

JO - Radiotherapy & Oncology

JF - Radiotherapy & Oncology

IS - 2

ER -

Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): Design and early dosimetric results of a randomized, multi-centre phase-III study

Keywords

Access to Document

Fingerprint

Cite this